U.S.S.N. 09/699,003 Filed: October 26, 2000 AMENDMENT

## Amendment

RECEIVED
CENTRAL FAX CENTER
JUN 2 3 2009

## In the Claims

1. (currently amended) A method for inducing an immune response against transformed, infected or diseased tissue in a patient comprising

selectively removing soluble cytokine receptor molecules <u>selected from the group</u> consisting of soluble tissue necrosis factor receptor-1 ("sTNFR-1"), soluble tissue necrosis factor receptor-2 ("sTNFR-2"), soluble interleukin-2 receptor ("sIL-2R"), soluble interleukin-1 receptor ("sIL-1R"), soluble interleukin-6 receptor ("sIL-6R"), and soluble interferon-gamma receptor ("sIFN-gammaR") from blood, plasma, or one or more components of the blood of the patient until the transformed, infected, or diseased tissue is reduced in size or is inflamed <del>or other positive indication is observed</del>.

- 2. (original) The method of claim 1 wherein the tissue is a solid tumor.
- 3. (original) The method of claim 1 wherein the components are removed from one blood volume.
- 4. (original) The method of claim 1 wherein the components are removed in multiple treatments.
- 5. (original) The method of claim 1 further comprising treating the tissue with an agent selected from the group consisting of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents, and radiation.
- 6. (original) The method of claim 5 wherein the agent is a cytokine and the cytokine is selected from the group consisting of GM-CSF, erythropoietin, thrombopoetin, G-CSF, M-CSF and SCF.
  - 7. (cancelled).

U.S.S.N. 09/699,003 Filed: October 26, 2000 AMENDMENT

- 8. (cancelled) The method of claim 1 wherein the soluble cytokine receptor molecules are selected from the group consisting of soluble tissue necrosis factor receptor-1 ("sTNFR-1"); and soluble tissue necrosis factor receptor-2 ("sTNFR-2"), soluble interleukin 2 receptor ("sIL 2R"), soluble interleukin-1-receptor ("sIL-1R"), soluble interleukin 6 receptor ("sIL-6R"); and soluble interferon gamma receptor ("sIFN gammaR").
- 9. (currently amended) The method of claim § 1 wherein the cytokine receptor molecules are removed by binding to the cytokine or to an antibody or antibody fragment immunoreactive with the cytokine receptor molecules.
- 10. (previously presented) The method of claim 9 wherein the cytokine or antibody or antibody fragments are immobilized in a filter or column through which the patient's blood or plasma is circulated prior to being returned to the patient.

Claims 11-20 (cancelled).